Binay Shah, MD, MHA – Binaytara Foundation
Dr. Binay Shah is a board-certified oncologist and hematologist. Dr. Shah’s area of interest is in health outcomes and health disparities among cancer patients, and he has published and presented over 125 papers in various journals and meetings. Read more here.
Shaji Kumar, MD – Mayo School of Medicine
Dr. Shaji Kumar is a hematologist at the Mayo School of Medicine. His research focuses on the development of novel drugs for the treatment of myeloma. Dr. Kumar’s research team evaluates the in vitro activity of novel drugs that, based on their mechanisms of action, are likely to have activity in the setting of myeloma. Dr. Kumar also evaluates novel combinations of different drugs to identify synergistic combinations that can result in better treatment responses and eventually better patient outcomes.
Deborah Stephens, MD – Huntsman Cancer Institute
Deborah Stephens, DO joined the Division of Hematology and Hematologic Malignancies as an Assistant Professor in 2014. She completed her internal medicine residency at Cleveland Clinic and fellowship training at Ohio State University. Dr. Stephens’s clinic focuses on patients with chronic lymphocytic leukemia (CLL) and lymphoma. Her primary research interests include developing new targeted therapies for patients with CLL and lymphoma, studying resistance to current therapies, and developing supportive therapies for complications of CLL. She is the Physician Leader of the Hematology Clinical Trials Division at Huntsman Cancer Institute and is the principal investigator on multiple clinical trials there. Read more here.
Elihu “Eli” Estey, MD – University of Washington
Dr. Estey is an expert in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). In addition to seeing patients at the UWMC and at SCCA, he has considerable experience in the design, conduction, and interpretation of clinical trials in AM. He is particularly interested in bringing data to bear on the clinical management of AML. Read more here.
David Aboulafia, MD – Virginia Mason
Dr. David Aboulafia is the Section Head in the Department of Hematology/Oncology at Virginia Mason Clinic and an Investigator in the Virginia Mason Community Clinical Oncology Program/SWOG. He is an active member of the AIDS Malignancy Consortium and chair of the AMC outreach, education, recruitment, and retention committee. He is also a Clinical Professor of Medicine in the Division of Hematology at the University of Washington.
Andrew Cowan, MD – University of Washington
Andrew Cowan, MD, is an assistant professor of medicine at the University of Washington and has a joint affiliation with the Fred Hutchinson Cancer Research Center. His clinical and research focus is on multiple myeloma and other plasma cell disorders. He first became interested in plasma cell disorders through a 1-year fellowship in amyloidosis at the Boston University Amyloid Center, in Boston, MA. Read more here.
Vivian G. Oehler, MD – Seattle Cancer Care Alliance
Dr. Vivian Oehler is a hematologic oncologist who cares for patients with leukemia and other blood disorders. She graduated from the Case Western Reserve University Medical School. She is an Associate Professor of Medicine in the Department of Hematology at the University of Washington. She is also an Associate Member at the Fred Hutch Clinical Research Division. Her research explores the genetic origins and drivers of those diseases. Read more here.
George Rodgers, MD, PhD – University of Utah Health Sciences Center
George M. Rodgers, MD, PhD is Professor of Medicine and Pathology at the University of Utah Health Sciences Center. He is also the Medical Director of the Coagulation Laboratory at ARUP Laboratories. He received his M.D. and Ph.D. degrees from Tulane University, did internal medicine training at Baylor College of Medicine, and received hematology fellowship training at UCSF.Dr. Rodgers’ clinical research interests include benign hematology, especially disorders of hemostasis and thrombosis. He has published over 200 journal articles and book chapters as well as 4 books, primarily on coagulation subjects. He is an associate editor of Wintrobe’s Clinical Hematology textbook.
Doris Quon, MD – Orthopedic Hemophilia Treatment Center
Dr. Quon is board certified in Hematology & Oncology and Internal Medicine. She obtained her M.D., Ph.D. at the UCLA David Geffen School of Medicine, and did her Residency in Internal Medicine as well as Fellowship in Hematology-Oncology at UCLA Medical Center. She first began her residency training at the Orthopedic Hemophilia Treatment Center (OHTC) back in 2000 and is currently a Medical Director of OHTC. She has an active role in coordinating the federally funded Region IX Hemophilia activities for the center and is the Medical Director of the Hemophilia Foundation of Southern California.
John P. Leonard, MD – Weill Cornell Medicine
Dr. John P. Leonard is the Richard T. Silver Distinguished Professor of Hematology and Medical Oncology and Senior Associate Dean for Innovation and Initiatives at Weill Cornell Medicine. He also serves as Executive Vice-Chair of the Weill Department of Medicine. Dr. Leonard received an undergraduate degree from Johns Hopkins University and a medical degree from the University of Virginia School of Medicine. He completed his residency in medicine at New York-Presbyterian/Weill Cornell Medical Center and Memorial Sloan Kettering Cancer Center. Read more here.
Srinivas Tantravahi, MD – University of Utah Health Sciences Center
Dr. Tantravahi has received his medical degree from Guntur medical college, India. He then completed an Internal Medicine residency and Hematology and Oncology fellowship training at the University of Utah Hospital. His clinical interests include multiple myeloma, stem cell transplantation, and myeloproliferative neoplasm. The focus of his research has been on the mechanisms of resistance of CML patients to tyrosine kinase inhibitor therapy. Read more here.
Ming Lim, MD – University of Utah
Dr. Ming Lim is an Assistant Professor in the Division of Hematology and Hematologic Malignancies at the University of Utah since October 2018. She earned her medical degree at Cambridge University, England, and completed her 2-year Foundation Training in the United Kingdom. She then completed a residency in internal medicine at the Mayo Clinic Rochester and fellowship training in hematology and oncology at the University of North Carolina at Chapel Hill. Read more here.
Jerald Radich, MD – Fred Hutch
Dr. Jerald Radich is a Member of the Clinical Research Division, the Director the Molecular Oncology Lab and the Kurt Enslein Endowed Chair at the Fred Hutchinson Cancer Research Center, and Professor of Medicine at the University of Washington School of Medicine. He is Chair of the Leukemia Translational Medicine Committee of the Southwest Oncology Group. He was the inaugural Chair of the National Cancer Institute and National Institute of Health Leukemia Steering Committee, and a past member of the Board of Scientific Counselors of the NIH Genome Research Institute. He is the past-chair of the CML Committee of the National Comprehensive Cancer Network, a member of the European Leukemia Network CML committees, and is on the Scientific Board of the International CML Foundation and the Max Foundation. He currently leads the Laboratory Committee of the NCI AML Precision Medicine Initiative and leads the Foundation of the NIH’s program in measurable residual disease in AML. Dr. Radich’s laboratory research centers on the molecular biology of response, resistance, and progression in adult and chronic leukemia. In addition, the CLIA Molecular Oncology Lab provides the molecular diagnostic support for many institutional, U.S. Intergroup, international, and pharmaceutical trials. He was awarded the International CML Foundation Award in 2017 and the Washington Global Health Alliance Partnership Award in 2019 for his lab’s work on diagnosing and monitoring CML in the developing world.